MRI Contrast Media Market - By Product (Extracellular Agents {Ionic, Non-ionic}, Hepatobiliary Agents), Type (Branded, Generics), Application (Neurological, Musculoskeletal, Cardiovascular, Cancer), End-use- Global Forecast, 2024-2032

MRI Contrast Media Market - By Product (Extracellular Agents {Ionic, Non-ionic}, Hepatobiliary Agents), Type (Branded, Generics), Application (Neurological, Musculoskeletal, Cardiovascular, Cancer), End-use- Global Forecast, 2024-2032

MRI Contrast Media Market Size

MRI Contrast Media Market size was valued USD 1.6 billion in 2023 and is expected to grow at a CAGR of 4.6% between 2024 and 2032. The market growth is driven by the growing prevalence of chronic diseases, rising demand for early diagnosis, and increased R&D investment and activities.
 

As reported by the American Cancer Society projected figures for new cancer cases and deaths in 2022 indicate an estimated 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the U.S. alone. Thus, rise in cancer/oncology cases is expected to spur the demand for early diagnosis.
 

MRI contrast media, also known as contrast agents, are imaging agents or the substances injected to enhance the visibility of the tissues or organs during MRI procedure. These agents contain the magnetism properties that alter the magnetic resonance properties of surrounding tissues, providing clearer and more detailed images. MRI contrast media assist in visualizing and characterizing abnormalities like tumors, inflammation, and vascular conditions during MRI scans with enhanced diagnostic precision.
 

COVID-19 Impact

The MRI contrast media market has experienced negative impact due to the COVID-19 pandemic. Disruptions in healthcare services, postponed the elective procedures along with the reallocation of resources for pandemic-related needs have led to a temporary decline in demand for diagnostic imaging, particularly in MRI. According to a report from IMV Medical Information Division, the pandemic is estimated to have resulted in a 35% decrease in MRI procedure volume in the U.S. alone in 2020. Thus, a negative impact on the contrast media market was observed in 2020.
 

MRI Contrast Media Market Trends

• The continual advancement with collaborative research for effective therapies and precise diagnostic results expect to explore opportunities in the market. For instance, in June 2023, a recent partnership between Philips and Polarean integrates multi-nuclei imaging from Philips’ 3T MR 7700 MRI system with Xenoview, a hyperpolarized Xenon-based MRI contrast agent. This collaboration enhances lung imaging detail and improves accuracy in measuring lung ventilation.
   
• Similarly, contrast media possess the capability to track the developments in brain, liver, or breast tumors, offering enhanced guidance in surgical interventions. With the expanding applications of MRI, procedures utilizing these contrast media are expected to rise. Therefore, the market is anticipated to grow in the coming years due to escalating healthcare spending, a surge in chronic diseases, research funding, collaborations, acquisitions, and increased public awareness.
   

MRI Contrast Media Market Analysis

Based on product, the MRI contrast media market is segmented into extracellular contrast agents, blood-pool agent, and hepatobiliary agents. The extracellular contrast agents are expected to lead the market, projecting the highest revenue of USD 1.9 billion by 2032.
 

• Extracellular contrast agents, primarily gadolinium-based agents, dominate the market due to their efficacy in enhancing image contrast. The gadolinium-based agents are administered intravenously and distribute in the extracellular space, highlighting vascular structures and aiding in the visualization of abnormalities.
   
• Further, the administration of gadolinium MRI contrast injections enhances diagnostic precision in conditions such as inflammatory and infectious diseases affecting the brain, spine, soft tissues, and bones. These injections improve image clarity, enabling radiologists to discern and locate issues more effectively.
   

Based on the type, the MRI contrast media market is classified into branded and generics. The branded segment dominated the market accounting for the highest share of 67.3% in 2023.
 

• Leading pharmaceutical companies frequently create exclusive formulations for contrast agents, which are favored for their well-established safety records, effectiveness, and widespread clinical acceptance.
   
• Also, the substantial investments made by these companies in research and development contribute to solidifying the competitive advantage of branded contrast agents.
   

Based on application, the MRI contrast media market is classified into neurological disorders, musculoskeletal disorders, cardiovascular disorders, gastrointestinal disorders, cancer detection, other application. The neurological disorders segment dominated the market accounting for the largest revenue in USD 735.1 million in 2023.
 

• The dominance segment is attributable to the development of specialized contrast agents tailored for neurological imaging has been a focal point for pharmaceutical innovators. These formulations aim to provide improved visualization of intricate neural structures, aiding in the identification and characterization of neurological disorders such as brain tumors, multiple sclerosis, and vascular abnormalities.
   

Based on end-use, the MRI contrast media market is classified into hospitals, diagnostic & imaging centers, research institutes and other end-users. The hospitals segment dominated the market anticipating its growth during the analysis period with a CAGR of 4.5%.
 

• Hospitals serve as the primary facilities for patients undergoing major diagnostic tests, making them the focal point, thereby contribute significantly to their substantial market share.
   
• The extensive research activities and the requisite economic and infrastructure capabilities, essential for procuring and storing contrast agents, are predominantly available within hospital settings, thus establishing their dominance in the market.
   

 In 2023, North America held a significant market share in the MRI contrast media market and is anticipated to dominate the market throughout the forecast period.
 

• Leading pharmaceutical companies in the region have been at the forefront of developing and introducing advanced contrast agents, incorporating cutting-edge imaging technologies to enhance diagnostic capabilities. These formulations often undergo rigorous scrutiny and adherence to regulatory protocols, emphasizing the commitment to safety and efficacy in clinical applications.
   
• The demand for MRI contrast media in North America is fueled by a robust healthcare ecosystem, encompassing state-of-the-art medical facilities and a proactive approach to adopting novel diagnostic technologies. Also, neurological imaging, oncology, and cardiovascular applications, in particular, have witnessed significant strides, with contrast agents playing a pivotal role in enabling detailed and precise diagnoses.
   

MRI Contrast Media Market Share

The pharmaceutical and biotechnology companies are actively operating in the market, leveraging their research capabilities and global presence. Strategic collaborations, product innovations, and regulatory compliance further strengthen their positions. The market is characterized by ongoing technological advancements and a focus on developing safer and more effective contrast agents, intensifying the competitive dynamics in this vital healthcare segment.
 

MRI Contrast Media Market Company

The prominent players operating in the MRI contrast media industry is as mentioned below

• Bayer HealthCare LLC
• Guerbet LLC
• GE HealthCare
• Lantheus Medical Imaging, Inc.
• B. Chemicals and Pharmaceuticals Ltd.
• Bracco
• BioPAL, Inc.
• Vitalquan, LLC
• Fresenius Kabi
• Polarean.
   

MRI Contrast Media Industry News

• In April 2023, GE Healthcare received marketing authorization of Pixxoscan, a macrocyclic, non-ionic gadolinium-based MRI contrast agent, in Austria. It is utilized in stress cardiac MR for diagnosing coronary artery disease. This launch is expected to expand the access to agents supporting diverse MRI procedures.
   
• In December 2021, Guerbet and Bracco Imaging S.p.A. have entered a global collaboration for Gadopiclenol, an advanced MRI contrast agent. With this collaboration, the company will independently commercialize the product under distinct brand names This collaborative agreement has strengthened both the company’s product portfolios on MRI platorm.
   

The MRI contrast media market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Product, 2018 – 2032 (USD Million)

• Extracellular contrast agents         
• Ionic
• Non-ionic 
• Blood-pool agent
• Hepatobiliary agents

By Type, 2018 – 2032 (USD Million)

• Branded
• Generics

By Application, 2018 – 2032 (USD Million)

• Neurological disorders
• Musculoskeletal disorders
• Cardiovascular disorders
• Gastrointestinal disorders
• Cancer detection
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Hospitals
• Diagnostic & imaging centers
• Research institutes
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa